BioMarin Anticipates FDA Approval Of Phenoptin In Late 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing strategies for the orphan drug are under development as BioMarin plans a 20-rep sales force expansion, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
BioMarin Submits Kuvan For Phenylketonuria
Firm is asking FDA for a priority review, which would potentially allow for a late 2007 launch of the orphan drug.
BioMarin Submits Kuvan For Phenylketonuria
Firm is asking FDA for a priority review, which would potentially allow for a late 2007 launch of the orphan drug.
BioMarin Begins Phase II Study Of 6R-BH4 For Sickle Cell Disease
Firm initiates treatment in sickle cell patients after stalling Phase IIb study of molecule in treatment of hypertension earlier this year.